Pharmacological  	Pharmacological  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	I-NP
fibromyalgia  	fibromyalgia  	 JJ	I-NP
Fibromyalgia  	Fibromyalgia  	 NNP	I-NP
( 	( 	 -LRB-	O
FM 	FM 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
a  	a  	 DT	O
common  	common  	 JJ	O
syndrome  	syndrome  	 NN	O
characterised  	characterised  	 NN	O
by  	by  	 IN	O
widespread  	widespread  	 JJ	O
pain  	pain  	 NN	O
and  	and  	 CC	O
at  	at  	 IN	O
least  	least  	 JJS	O
11 	11 	 CD	O
/ 	/ 	 CD	O
18  	18  	 CD	O
painful  	painful  	 JJ	O
tender  	tender  	 NN	B-NP
points  	points  	 NNS	I-NP
that  	that  	 WDT	O
requires  	requires  	 VBZ	O
multimodal  	multimodal  	 JJ	B-NP
pharmacological  	pharmacological  	 JJ	I-NP
treatment  	treatment  	 NN	I-NP
also  	also  	 RB	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
non-pharmacological  	non-pharmacological  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
Various  	Various  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
currently  	currently  	 RB	O
are  	are  	 VBP	O
available  	available  	 JJ	O
to  	to  	 TO	O
control  	control  	 VB	O
the  	the  	 DT	O
complex  	complex  	 JJ	O
and  	and  	 CC	O
different  	different  	 JJ	O
symptoms  	symptoms  	 NNS	B-NP
reported  	reported  	 VBD	O
by  	by  	 IN	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Only  	Only  	 RB	O
three  	three  	 CD	O
drugs  	drugs  	 NNS	O
( 	( 	 -LRB-	O
duloxetine 	duloxetine 	 UH	B-NP
,  	,  	 ,	O
milnacipram 	milnacipram 	 NN	B-NP
,  	,  	 ,	O
pregabalin 	pregabalin 	 CD	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
approved  	approved  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
American  	American  	 NNP	O
Food  	Food  	 NNP	B-NP
and  	and  	 CC	I-NP
Drug  	Drug  	 NNP	I-NP
Administration  	Administration  	 NNP	I-NP
( 	( 	 -LRB-	O
FDA 	FDA 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
none  	none  	 NN	O
by  	by  	 IN	O
the  	the  	 DT	O
European  	European  	 NNP	O
Medicines  	Medicines  	 NNP	O
Agency  	Agency  	 NNP	B-NP
( 	( 	 -LRB-	O
EMEA 	EMEA 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
consequently 	consequently 	 RB	O
,  	,  	 ,	O
off-label  	off-label  	 JJ	B-NP
use  	use  	 NN	I-NP
is  	is  	 VBZ	O
habitual  	habitual  	 VBN	O
in  	in  	 IN	O
Europe 	Europe 	 NNP	O
.  	.  	 .	O
Most  	Most  	 JJS	O
of  	of  	 IN	O
the  	the  	 DT	O
drugs  	drugs  	 NNS	O
improve  	improve  	 VBP	O
only  	only  	 RB	O
one  	one  	 CD	O
or  	or  	 CC	O
two  	two  	 CD	O
symptoms 	symptoms 	 NNS	B-NP
;  	;  	 :	O
no  	no  	 DT	O
drug  	drug  	 NN	O
capable  	capable  	 NN	O
of  	of  	 IN	O
overall  	overall  	 JJ	O
symptom  	symptom  	 NN	B-NP
control  	control  	 NN	I-NP
is  	is  	 VBZ	O
yet  	yet  	 RB	O
available 	available 	 JJ	O
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
different  	different  	 JJ	O
classes  	classes  	 NNS	O
of  	of  	 IN	O
drugs  	drugs  	 NNS	O
with  	with  	 IN	O
different  	different  	 JJ	O
mechanisms  	mechanisms  	 NNS	O
of  	of  	 IN	O
action  	action  	 NN	O
are  	are  	 VBP	O
used  	used  	 VBN	O
off-label 	off-label 	 JJ	B-NP
,  	,  	 ,	O
including  	including  	 VBG	O
tricyclic  	tricyclic  	 JJ	B-NP
antidepressants  	antidepressants  	 NNS	I-NP
( 	( 	 -LRB-	O
TCAs 	TCAs 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
selective  	selective  	 FW	B-NP
serotonin  	serotonin  	 FW	I-NP
reuptake  	reuptake  	 FW	I-NP
inhibitors  	inhibitors  	 FW	I-NP
( 	( 	 -LRB-	O
SSRIs 	SSRIs 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
serotonin  	serotonin  	 FW	B-NP
norepinephrine  	norepinephrine  	 FW	I-NP
reuptake  	reuptake  	 FW	I-NP
inhibitors  	inhibitors  	 FW	I-NP
( 	( 	 -LRB-	O
SNRIs 	SNRIs 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
opioids 	opioids 	 NN	B-NP
,  	,  	 ,	O
non-steroidal  	non-steroidal  	 JJ	B-NP
anti-inflammatory  	anti-inflammatory  	 JJ	I-NP
drugs  	drugs  	 NNS	I-NP
( 	( 	 -LRB-	O
NSAIDs 	NSAIDs 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
growth  	growth  	 NN	B-NP
hormone 	hormone 	 NN	I-NP
,  	,  	 ,	O
corticosteroids  	corticosteroids  	 NN	B-NP
and  	and  	 CC	O
sedative  	sedative  	 JJ	B-NP
hypnotics 	hypnotics 	 NN	I-NP
.  	.  	 .	O
As  	As  	 IN	O
no  	no  	 DT	O
single  	single  	 JJ	O
drug  	drug  	 NN	O
fully  	fully  	 RB	O
manages  	manages  	 VBZ	O
FM  	FM  	 JJ	B-NP
symptoms 	symptoms 	 NNS	I-NP
,  	,  	 ,	O
multicomponent  	multicomponent  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
should  	should  	 MD	O
be  	be  	 VB	O
used  	used  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
beginning 	beginning 	 NN	O
.  	.  	 .	O
Various  	Various  	 JJ	B-NP
pharmacological  	pharmacological  	 JJ	I-NP
treatments  	treatments  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
used  	used  	 VBN	O
to  	to  	 TO	O
treat  	treat  	 VB	O
FM  	FM  	 NN	B-NP
with  	with  	 IN	O
inconclusive  	inconclusive  	 JJ	B-NP
results 	results 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
gradually  	gradually  	 RB	O
increasing  	increasing  	 VBG	O
low  	low  	 JJ	O
doses  	doses  	 NN	O
is  	is  	 VBZ	O
suggested  	suggested  	 VBN	O
in  	in  	 IN	O
order  	order  	 NN	O
to  	to  	 TO	O
maximise  	maximise  	 VB	O
efficacy 	efficacy 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
best  	best  	 JJS	O
treatment  	treatment  	 NN	O
should  	should  	 MD	O
be  	be  	 VB	O
individualised  	individualised  	 NNS	O
and  	and  	 CC	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
patient  	patient  	 JJ	O
education  	education  	 NN	O
and  	and  	 CC	O
non-pharmacological  	non-pharmacological  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
